Skip to main
BMEA

BMEA Stock Forecast & Price Target

BMEA Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 29%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Biomea Fusion Inc. demonstrates a strong positive outlook due to its innovative pipeline of oral covalent small-molecule drugs, particularly icovamenib, which has shown durable glycemic control and significant reductions in HbA1c in early clinical trials. Furthermore, the company’s progress with BMF-650, exhibiting promising preclinical weight reduction and glucose-lowering effects, coupled with its favorable safety data from chronic toxicology studies, reinforces the potential for these candidates in treating diabetes and obesity. Lastly, the financials indicate a notable improvement, with a reduced net loss of $16.4 million for Q3 2025 compared to $32.8 million in Q3 2024, alongside a decrease in operating expenses by over 50% year-over-year, highlighting enhanced financial efficiency.

Bears say

Biomea Fusion Inc. reported a significant reduction in Research and Development (R&D) expenses, dropping from $27.2 million in Q3 2024 to $14.4 million in Q3 2025, alongside a decrease in General and Administrative (G&A) expenses from $6.8 million to $4.2 million. This reduction in expenses raises concerns about the company's ability to effectively advance its clinical programs and maintain growth in research output, potentially indicating financial constraints. Furthermore, the adjustment of the price target from $16.00 to $12.00 reflects a reassessment of the company's financial outlook, exacerbating the negative sentiment surrounding its stock.

BMEA has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 29% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biomea Fusion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biomea Fusion Inc (BMEA) Forecast

Analysts have given BMEA a Buy based on their latest research and market trends.

According to 7 analysts, BMEA has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biomea Fusion Inc (BMEA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.